Maximizing Asset Value in Rare Kidney Disease: Expanding from IgA to New Indications & Designing Proof-of-Concept Trials to Accelerate Development
- Leveraging clinical success in one indication to de-risk expansion into new rare kidney diseases
- Designing efficient proof-of-concept trials in small, heterogeneous patient populations
- Aligning indication expansion strategies with regulatory expectations and endpoint selection
- Balancing speed, cost, and probability of success when advancing pipeline-in-aproduct strategies